References
- Devi GR . siRNA-based approaches in cancer therapy. Cancer Gene Ther.13(9), 819–829 (2006).
- Blackburn EH . Telomerases. Annu. Rev. Biochem.61(5), 113–129 (1992).
- Shay JW . Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell2(4), 257–265 (2002).
- Shay JW . Zou Y, Hiyama E, Wright WE. Telomerase and cancer. Hum. Mol. Genet.10(7), 677–685 (2001).
- Gary DJ . Puri N, Won YY. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J. Control. Release121(1–2), 64–73 (2007).
- Jeong JH . Christensen LV, Yockman JW et al. Reducible poly(amido ethylenimine) directed to enhance RNA interference. Biomaterials28(10), 1912–1917 (2007).
- Meng FH . Hennink WE, Zhong Z. Reduction-sensitive polymers and bioconjugates for biomedical applications. Biomaterials30(12), 2180–2198 (2009).
- Lin C . Engbersen JFJ. The role of the disulfide group in disulfide-based polymeric gene carriers. Exp. Opin. Drug Del.6(4), 421–439 (2009).
- Xia W , WangP, LinCet al. Bioreducible polyethylenimine-delivered siRNA targeting human telomerase reverse transcriptase inhibits HepG2 cell growth in vitro and in vivo. J. Control. Rel. 157(3), 427–436 (2012).
- Bonnet ME . Erbacher P, Bolcato-Bellemin AL. Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response. Pharm. Res.25(12), 2972–2982 (2008).
- Rautsi O . Lehmusvaara S, Salonen T et al. Type I interferon response against viral and non-viral gene transfer in human tumor and primary cell lines. J. Gene Med.9(2), 122–135 (2007).
- Lin C . Engbersen JFJ. PEGylated bioreducible poly(amido amine)s for non-viral gene delivery. Mat. Sci. Eng. Bio. S.31(7), 1330–1337 (2011).